BioStock: Respiratorius looks forward to exciting autumn
It has been an eventful spring for Lund-based drug developer Respiratorius. The company’s main candidate VAL001 continues to advance towards phase III studies, whilst several important milestones have been reached for the lung project RCD405, which previously went under the project name RESP9000. BioStock contacted the company’s CEO Johan Drott to get his view on the beginning of 2021 and hear what he envisions for the rest of the year.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se